COMPANY
Clinical Phase 2
Keywords: protein therapeutics Oncology Melanoma Ovarian Cancer NSCLC Non Small Cell Lung Cancer Colorectal Cancer Pancreatic Cancer CRC Colon Cancer Breast Cancer Gastric Cancer Esophagogastric Junction Cancer Head and Neck Cancer Urothelial Cancer Bladder Cancer E-602
Location: Waltham, MA · source · Oct 15, 2026
Profile checked Oct 10, 2026
Timeline
- Trial start Phase 1/Phase 2: Glycan Mediated Immune Regulation With a Bi-Sialidase Fusion Protein (GLIMMER-01) source ↗
Clinical trials (lead sponsor) 1
| Record | Title | Phase | Status | Start | Primary completion |
|---|
| NCT05259696 | Glycan Mediated Immune Regulation With a Bi-Sialidase Fusion Protein (GLIMMER-01) | Phase 1/Phase 2 | Completed | Feb 11, 2022 | Oct 24, 2024 (actual) |
